Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
For cisplatin-ineligible pT4N0M0 renal pelvis UTUC without prior neoadjuvant therapy, do you prefer adjuvant carboplatin/gemcitabine (POUT) or immunotherapy (CheckMate 274)?
Related Questions
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
In light of evidence supporting enfortumab vedotin with pembrolizumab (EVP) in muscle-invasive urothelial cancer, would one consider perioperative EVP for node-negative high-risk UTUC?
For patients starting Pluvicto, do you have patients stop their ARPI?
In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?
How do you interpret nodes with minimal increased uptake on PSMA PET in prostate cancer?
Do you advise patients with a personal or family history of germ cell tumors to avoid endocrine disruptors such as marijuana/CBD, lavender oils, or tea tree oils?
How would do manage stage II/III Muscle invasive bladder cancer with large cell neuroendocrine histology?
How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
How would you treat a patient with isolated CNS relapse of seminoma?
Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?
